Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.8% - Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price rose 0.8% on Monday . The company traded as high as $6.07 and last traded at $5.78. Approximately 5,183,271 shares changed hands during trading, a decline of 58% from the average daily volume of 12,256,373 shares. The stock had previously closed at $5.73.

Analysts Set New Price Targets

RXRX has been the topic of several research reports. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Morgan Stanley cut their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Finally, Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $8.20.

Recursion Pharmaceuticals Price Performance

The business's 50 day moving average is $5.82 and its two-hundred day moving average is $6.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market capitalization of $2.29 billion, a PE ratio of -3.73 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company earned ($0.42) EPS. The firm's revenue was down 57.8% compared to the same quarter last year. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. lifted its holdings in shares of Recursion Pharmaceuticals by 8.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 53,622 shares of the company's stock worth $284,000 after acquiring an additional 4,349 shares during the last quarter. ADG Wealth Management Group LLC bought a new position in shares of Recursion Pharmaceuticals during the first quarter valued at about $55,000. CWM LLC increased its holdings in shares of Recursion Pharmaceuticals by 140.2% in the first quarter. CWM LLC now owns 24,094 shares of the company's stock worth $127,000 after buying an additional 14,065 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Recursion Pharmaceuticals by 21.8% in the 1st quarter. New York State Common Retirement Fund now owns 77,175 shares of the company's stock valued at $408,000 after acquiring an additional 13,800 shares during the last quarter. Finally, Cerity Partners LLC purchased a new stake in Recursion Pharmaceuticals during the 1st quarter valued at about $332,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.